Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 4
2006 5
2007 3
2008 2
2009 3
2010 6
2011 10
2012 9
2013 12
2014 11
2015 5
2016 12
2017 11
2018 13
2019 7
2020 11
2021 14
2022 17
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: kishimoto j. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Among authors: kishimoto j. J Thorac Oncol. 2021 Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27. J Thorac Oncol. 2021. PMID: 33915251 Free article. Clinical Trial.
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I. Ibusuki R, et al. Among authors: kishimoto j. Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215. doi: 10.21037/tlcr-22-393. Transl Lung Cancer Res. 2022. PMID: 36519019 Free PMC article.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: kishimoto j. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Clinical Trial.
Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial.
Hosokawa K, Abe K, Kishimoto J, Kobayakawa Y, Todaka K, Tamura Y, Tatsumi K, Inami T, Ikeda N, Taniguchi Y, Minatsuki S, Murohara T, Yasuda S, Fukuda K, Tsutsui H. Hosokawa K, et al. Among authors: kishimoto j. BMJ Open. 2022 Jul 19;12(7):e061225. doi: 10.1136/bmjopen-2022-061225. BMJ Open. 2022. PMID: 37070473 Free PMC article.
Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, Sakamoto T, Murakami H, Kishimoto J, Matsumoto S, Nakanishi Y, Goto K, Okamoto I. Iwama E, et al. Among authors: kishimoto j. Eur J Cancer. 2022 Feb;162:99-106. doi: 10.1016/j.ejca.2021.11.021. Epub 2021 Dec 24. Eur J Cancer. 2022. PMID: 34959152 Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of NK-104-NP.
Nakano K, Matoba T, Koga JI, Kashihara Y, Fukae M, Ieiri I, Shiramoto M, Irie S, Kishimoto J, Todaka K, Egashira K. Nakano K, et al. Among authors: kishimoto j. Int Heart J. 2018 Sep 26;59(5):1015-1025. doi: 10.1536/ihj.17-555. Epub 2018 Aug 29. Int Heart J. 2018. PMID: 30158384 Free article. Clinical Trial.
A novel quantitative indicator for disease progression rate in amyotrophic lateral sclerosis.
Kobayakawa Y, Todaka K, Hashimoto Y, Ko S, Shiraishi W, Kishimoto J, Kira JI, Yamasaki R, Isobe N; Pooled Resource Open-Access ALS Clinical Trials Consortium. Kobayakawa Y, et al. Among authors: kishimoto j. J Neurol Sci. 2022 Nov 15;442:120389. doi: 10.1016/j.jns.2022.120389. Epub 2022 Aug 24. J Neurol Sci. 2022. PMID: 36041329 Free article.
Deep Learning of ECG for the Prediction of Postoperative Atrial Fibrillation.
Tohyama T, Ide T, Ikeda M, Nagata T, Tagawa K, Hirose M, Funakoshi K, Sakamoto K, Kishimoto J, Todaka K, Nakashima N, Tsutsui H. Tohyama T, et al. Among authors: kishimoto j. Circ Arrhythm Electrophysiol. 2023 Feb;16(2):e011579. doi: 10.1161/CIRCEP.122.011579. Epub 2023 Jan 30. Circ Arrhythm Electrophysiol. 2023. PMID: 36716179 No abstract available.
Blood biomarkers of Hikikomori, a severe social withdrawal syndrome.
Hayakawa K, Kato TA, Watabe M, Teo AR, Horikawa H, Kuwano N, Shimokawa N, Sato-Kasai M, Kubo H, Ohgidani M, Sagata N, Toda H, Tateno M, Shinfuku N, Kishimoto J, Kanba S. Hayakawa K, et al. Among authors: kishimoto j. Sci Rep. 2018 Feb 13;8(1):2884. doi: 10.1038/s41598-018-21260-w. Sci Rep. 2018. PMID: 29440704 Free PMC article.
142 results